FY2030 Earnings Forecast for AGIO Issued By HC Wainwright

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Investment analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research note issued to investors on Thursday, February 12th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will post earnings of $2.92 per share for the year. HC Wainwright currently has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share.

Other analysts also recently issued reports about the company. Truist Financial lifted their target price on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, December 29th. The Goldman Sachs Group lowered their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, November 20th. Leerink Partners upped their target price on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, December 26th. Finally, Citigroup reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Friday, December 26th. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $39.78.

Agios Pharmaceuticals Stock Down 0.4%

Shares of Agios Pharmaceuticals stock opened at $27.96 on Friday. The stock’s fifty day moving average is $27.39 and its two-hundred day moving average is $34.07. The company has a market capitalization of $1.63 billion, a PE ratio of -3.93 and a beta of 0.91. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00.

Insider Activity

In related news, CEO Brian Goff sold 18,703 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $506,664.27. Following the completion of the sale, the chief executive officer directly owned 136,583 shares in the company, valued at $3,700,033.47. This trade represents a 12.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Cecilia Jones sold 2,932 shares of the business’s stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the sale, the chief financial officer directly owned 37,394 shares in the company, valued at $1,013,003.46. This trade represents a 7.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 33,303 shares of company stock valued at $901,977. 4.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently modified their holdings of AGIO. Wellington Management Group LLP boosted its holdings in Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after buying an additional 2,049,287 shares in the last quarter. State Street Corp raised its holdings in shares of Agios Pharmaceuticals by 37.4% during the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after acquiring an additional 845,433 shares during the last quarter. TCG Crossover Management LLC lifted its position in shares of Agios Pharmaceuticals by 105.2% in the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after acquiring an additional 733,038 shares in the last quarter. Capital International Investors purchased a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $19,159,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Agios Pharmaceuticals in the third quarter worth approximately $19,889,000.

Agios Pharmaceuticals News Summary

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — Agios reported revenue of $19.97M (vs. ~ $12.1M est.) and an EPS loss narrower than expected (‑$1.85 vs. ‑$1.97 est.), driven in part by a 49% year‑over‑year increase in PYRUKYND (mitapivat) sales. The release also included the quarterly slide deck and call. Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst upgrade / higher price target — HC Wainwright reiterated a Buy and raised its price target to $65 (from $62), implying substantial upside versus current levels; the firm also published bullish FY2030 estimates. This can support investor optimism about long‑term upside. Benzinga: HC Wainwright raises price target
• Neutral Sentiment: Pipeline and commercialization milestones — AQVESME (mitapivat) is now available in the U.S. for thalassemia after FDA approval; Agios plans a pre‑sNDA meeting for mitapivat in sickle cell disease in Q1 and its Phase 2 tebapivat sickle cell trial is fully enrolled with topline expected in H2 2026. These are important milestones but outcomes/timing remain uncertain. Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Investor materials available — the earnings call transcript and presentation were posted (useful for deep dives into revenue mix, commercialization cadence and R&D spend). Agios Pharmaceuticals 2025 Q4 – Results – Earnings Call Presentation
• Neutral Sentiment: Short‑interest data appears inconsistent — recent reports show zero shares shorted (with NaN changes), suggesting a likely data anomaly rather than a material change in short positioning; treat this item as noisy.
• Negative Sentiment: Profitability and valuation headwinds — Agios remains unprofitable (very negative net margin and negative ROE reported) and the stock is trading below its 200‑day moving average, which may pressure sentiment until consistent positive cash‑flow trends appear. Agios Q4 earnings snapshot and transcript

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.